Hepatitis C

NAFLD resulted in a number of other negative outcomes, including sleep disturbance, cardiovascular disease, significant hepatic fibrosis, and advanced hepatic fibrosis.

The association between cumulative BMI and risk of NAFLD was more pronounced in women and younger participants.

A significantly lower rate of C difficile resolution was found in the placebo group compared to the FMT group.

RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic.

This risk also increased with age and was amplified in patients with HCV compared to patients without HCV.

Concurrent metabolic syndrome was independently linked to a worse overall and recurrence-free survival rates.

In the group positive for HCV by RNA testing in the emergency department, the linkage to care was just 44.1%, compared to 67.6% for patients in outpatient clinics and 50.9% for patients in inpatient units.

The inter-relationship of HPCs, HSCs, and macrophages was influenced by the stage of fibrosis, but not BMI.

The investigators sequenced HBsAg and found no amino acid substitution.

It is the first FDA-approved product indicated to improve kidney function in adults with HRS.

Model results were sensitive to the probability of hernia recurrence and hernia incarceration and utility decrement in the symptomatic hernia state.

Patients with both COVID-19 and HBV had a significantly higher in-hospital mortality rate and were more likely to develop severe disease compared to patients with only COVID-19 infections.

The highest global cirrhosis prevalence was found in the East and Southeast Asia, mainly caused by high levels of hepatitis prevalence in those areas.

The investigators found that the HCV viremia/HIV-positive group had a higher risk of HCV mother-to-child transmission.

The odds of HBV seroprevalence in participants with no or primary education was higher than individuals with secondary level education or higher.

NAFLD patients had a 13% higher risk of developing IBS after multivariable adjustment compared to patients without NAFLD.

In the study, 60.4% achieved resolution of ascites, encephalopathy, and absence of recurrent variceal bleeding for at least 12 months.

For liver-related deaths, 90% were from liver cancer, while the most common cause of non-liver-related deaths was malignancy.

The treatment is the first pediatric indication of the treatment and the first treatment for younger patients with cGVHD.

Occult HBV infection prevalence in blood donors was 0.06% in low-endemicity countries, 0.12% in intermediate-endemicity countries, and 0.98% in high-endemicity countries.

Some noticeable presenting features included jaundice, vomiting, and diarrhea.

The 10-year cumulative incidences for HCC and mortality were significantly higher in the HBV cohort with heavy alcoholism than it was for either HBV alone or alcoholism alone.

Investigators articulated the development and validation of an enzyme-linked immunoassay against hepatitis C virus (HCV). They suggest the implementation of this low cost assay among at-risk populations.

The increase does not appear to have a negative impact on post transplant survival, investigators say.

There are several early phase trials underway for new hepatitis B virus treatments.